FEATURED ARTICLES

• How ReTrans Supports Smarter Literature Surveillance In Pharmacovigilance

  Smarter literature surveillance uses automation, expert review, and targeted translation to handle growing volumes, improve signal detection, and reduce manual PV workload.

• From Submission Document To Lifecycle Safety Tool: Why RMPs Need Ongoing Attention

  Actively maintained risk management plans improve safety oversight, data alignment, and regulatory confidence well beyond initial approval milestones.

• Which FIH Decisions Are Hardest To Reverse Later?

  Early oncology trial decisions can lock in risk, shape regulatory confidence, and limit flexibility. Knowing which choices are hardest to reverse protects optionality and credibility.

• Harnessing AI for Pre-Award Landscape Analysis And Site Selection

  AI-driven insights transform site selection and feasibility, enabling faster decisions and reducing risk. Predictive modeling and real-time data improve pre-award planning and trial outcomes.

• Medical Insight's Role In Early-Phase Clinical Development

  Medical insight reduces risk, strengthens protocols, and accelerates timelines — enhancing safety, feasibility, and collaboration for successful trials and reliable outcomes.

• Why Early Medical Assessment Matters In Clinical Trials

  Early medical assessment reduces risk, improves patient selection, and avoids trial delays. Learn how starting early boosts compliance, speeds timelines, and protects participants and results.

• How To Implement Adaptive Dose-Escalation Designs In Oncology Trials

  By incorporating flexibility, statistical rigor, and continuous learning, adaptive designs strengthen early-phase oncology programs and support faster, more confident progression into later-stage development.

• Gene Therapies For Rare Diseases: Platforms, Modalities, And Delivery Systems

  Examine the treatment landscape for rare diseases and the rapid evolution of gene therapy across three key dimensions: editing platforms, delivery modalities, and delivery vehicles.

• Why Inclusive Clinical Trials Win On Science, Speed, And Spend

  Sponsors who proactively integrate diversity into their trial designs from the earliest phases are finding that it’s not only a matter of fairness but a strategic advantage.

• How High-Performing Trials Operationalize Health Equity Early

  Explore how embedding inclusion early in clinical development enhances enrollment, strengthens data integrity, and improves outcomes, especially in oncology and rare disease trials.

• The Strategic Role Of Biostatistics In Clinical Trials

  Early biostatistical input strengthens trial design, reduces risk, and ensures meaningful outcomes while strategic involvement drives smarter decisions. Learn why timing and collaboration matter.

• Understanding Trauma And Support In Clinical Trials

  Trauma shapes how families engage with clinical trials, influencing adherence, decision-making, and data quality. Explore how a patient-centered, empathetic approach is essential to build trust.

• Prioritizing Patient Voices

  Patient-reported outcomes are redefining how rare oncology trials measure therapeutic impact. Explore how they offer insight into patient experience to improve engagement and guide research.

• Pre-IND CMC Checklist For Regulatory Success

  Learn how to prepare CMC documentation that meets regulatory expectations, and explore key elements for a successful Pre-IND submission to avoid common delays in the review process.

• Delivering Successful Cell And Gene Therapy Trials

  Successfully executing complex cell and gene therapy trials hinges on meticulous operational strategies and a patient-centric approach.

• Designing Successful Cell And Gene Therapy Trials

  Designing cell and gene therapy trials requires specialized strategies to navigate unique complexities, ensuring successful and compliant development.

• Best Biostatistics Practices To Drive Clinical Trial Success

  Strong biostatistical practices are essential for trial success. Utilize this checklist of best practices for biostatistics in clinical trials, from early planning to regulatory submission.

• The Path Forward In Oncology Trials

  A comprehensive site support model is crucial for navigating the complexities of modern oncology trials and accelerating drug development.

• Creating Operational Efficiency And Competitive Edge

  Site networks offer a strategic approach to oncology clinical trials by accelerating study startup and expanding access to diverse patient populations.

• Strategic CMC Considerations For Pre-IND Meetings: Setting The Stage For A Successful TPP

  In biotechnology, the Pre-Investigational New Drug (Pre-IND) stage is a critical juncture. Explore the pivotal role of Chemistry, Manufacturing, and Controls (CMC) in navigating this phase.